Indication

Liver cell carcinoma

Liver cell carcinoma, also known as hepatocellular carcinoma, is a primary malignancy of the digestive and hepatobiliary system that originates directly from hepatocytes. Read more about Liver cell carcinoma

21 drugs 14 manufacturers

Advertisement

Drugs that treat it

Common Liver cell carcinoma therapies.

Showing 10–18 of 21 drugs

TECENTRIQ (atezolizumab)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·SMALL CELL LUNG CARCINOMA·+8
GENENTECH

IMFINZI (durvalumab)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·BILIARY TRACT MALIGNANCY·+10
AstraZeneca Pharmaceuticals

IMJUDO (tremelimumab-actl)

ANTINEOPLASTIC-CYTOTOXIC T-LYMP. ANTIGEN (CTLA-4),R-MC ANTIB·LIVER CELL CARCINOMA·+1
AstraZeneca Pharmaceuticals
Filter & compare in the drug finder →Opens the drug finder with Liver cell carcinoma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Liver cell carcinoma.

Liver cell carcinoma, also known as hepatocellular carcinoma, is a primary malignancy of the digestive and hepatobiliary system that originates directly from hepatocytes.

It represents the predominant histological subtype of primary liver cancer and most commonly develops in older adults and individuals with underlying chronic hepatic disease.

Pathophysiologically, it typically arises in the setting of persistent hepatic inflammation, fibrosis, and cirrhosis driven by chronic hepatitis B or C viral infection, alcohol-associated liver disease, or metabolic dysfunction-associated steatohepatitis.

Clinical features frequently include right upper quadrant abdominal pain, hepatomegaly, jaundice, weight loss, or decompensation of preexisting cirrhosis, often alongside elevated serum alpha-fetoprotein levels.

Personalize your experience

Follow Liver cell carcinoma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it